GleamWall
中文EN

PBYI PUMA BIOTECHNOLOGY, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%

Margins

Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%

Returns

ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x

Leverage & solvency

Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x

Cash quality & payout

Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$55.06M$56.50M$44.81M$75.45M$54.48M$52.44M$46.01M$59.08M
Cost of revenue$15.20M$12.47M$10.42M$23.13M$12.17M$12.30M$10.56M$13.92M
Gross profit$39.86M$44.03M$34.39M$52.33M$42.30M$40.13M$35.45M$45.16M
R&D expense$18.28M$18.89M$19.80M$16.84M$15.91M$15.45M$13.86M$15.17M
SG&A expense$16.30M$17.55M$18.42M$18.38M$16.82M$18.05M$17.60M$16.62M
Operating income$5.27M$7.58M-$3.83M$17.11M$9.57M$6.64M$3.98M$13.37M
Interest expense$0$180,000$731,000$1.12M$1.49M$1.84M$2.18M$2.62M
Pretax income$6.17M$8.24M-$3.43M$17.11M$9.24M$6.17M$3.27M$12.24M
Income tax———————-$7.07M
Net income$5.96M$8.19M-$3.75M$13.44M$8.84M$5.86M$2.97M$19.30M
EBITDA$7.73M$10.10M-$1.24M$19.76M$9.67M$6.74M$6.78M$16.21M
EPS (basic)0.120.16-0.07—0.180.120.06—
EPS (diluted)0.110.16-0.07—0.170.120.06—
Weighted avg. shares (diluted)53.12M52.60M50.85M—50.93M50.14M49.91M—
Balance sheet
Cash & equivalents$41.55M$36.54M$36.19M$29.64M$53.52M$54.66M$63.03M$69.22M
Short-term investments$67.03M$57.37M$65.35M$67.89M$40.86M$41.36M$30.14M$31.75M
Receivables$32.83M$34.06M$26.33M$53.65M$33.56M$25.91M$25.17M$32.01M
Inventory$11.49M$13.32M$8.69M$5.51M$9.48M$8.59M$8.75M$8.72M
Current assets$157.63M$145.07M$142.26M$162.69M$143.58M$136.58M$132.51M$147.66M
PP&E, net$84,000$103,000$124,000$187,000$305,000$388,000$474,000$515,000
Intangibles———$41.39M———$51.13M
Total assets$202.77M$192.74M$192.70M$216.30M$202.86M$194.92M$196.18M$213.33M
Current liabilities$51.97M$49.83M$59.74M$81.25M$82.73M$79.10M$86.66M$96.11M
Short-term debt$0$0$11.28M$22.52M$33.72M$34.00M$45.33M$45.33M
Long-term debt—$0$0$0$0$10.87M$10.65M$21.72M
Total debt—$0$11.28M$22.52M$33.72M$44.87M$55.98M$67.05M
Total liabilities$56.15M$54.19M$64.28M$85.96M$87.59M$90.20M$99.07M$121.21M
Shareholders' equity$146.61M$138.54M$128.42M$130.34M$115.27M$104.72M$97.11M$92.12M
Net debt—-$36.54M-$24.91M-$7.11M-$19.81M-$9.80M-$7.05M-$2.17M
Shares outstanding51.69M51.10M50.88M50.41M50.38M49.89M49.62M49.11M
Cash flow statement
Operating cash flow$14.58M$1.62M$15.42M$14.42M$9.69M$14.08M$3.61M$15.61M
Capital expenditure$0$0$0-$36,000$26,000$20,000$61,000$16,000
Free cash flow$14.58M$1.62M$15.42M$14.46M$9.66M$14.06M$3.55M$15.59M
Investing cash flow-$9.71M$7.97M$2.47M-$26.98M$506,000-$11.25M$1.53M-$2.32M
Financing cash flow$146,000-$11.34M-$11.33M-$11.33M-$11.33M-$11.20M-$11.33M-$11.33M
Depreciation & amortization$2.45M$2.52M$2.58M$2.66M$100,000$100,000$2.80M$2.84M
Stock-based compensation$2.02M$1.95M$1.90M$1.62M$1.67M$1.63M$2.03M$1.75M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.